Vaxxinity up 8% following phase 1 data on Parkinson's vaccine

• Vaxxinity (NASDAQ:VAXX) is up 9% in premarket trading after reporting promising phase 1 results on UB-312, its vaccine candidate for Parkinson's disease.
• In the trial, the asset was well-tolerated and induced anti-alpha-synuclein antibody responses in patients with early Parkinson's.
• "UB-312 was observed to safely break immune tolerance, inducing antibodies against toxic aggregated forms of alpha-synuclein," CEO Mei Mei Hu said. "Importantly, these antibodies crossed the blood brain barrier, and the data also suggest potential target engagement in the periphery, where pathological alpha-synuclein is known to be concentrated."

More on Vaxxinity

• Vaxxinity: Potential Strong Upsides Ahead

• Vaxxinity GAAP EPS of -$0.16 in-line